A prospective, multi-centre, open-label study to establish the equipotent dose ratio after switching from [the remainder of this trial title is not currently available]

Trial Profile

A prospective, multi-centre, open-label study to establish the equipotent dose ratio after switching from [the remainder of this trial title is not currently available]

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Buprenorphine (Primary) ; Morphine
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Nov 2016 Status changed to discontinued.
    • 09 Nov 2012 Additional lead trial centre identified as reported by EudraCT.
    • 09 Nov 2012 Planned number of patients changed from 10 to 180 as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top